CA2983342A1 - Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders - Google Patents

Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders Download PDF

Info

Publication number
CA2983342A1
CA2983342A1 CA2983342A CA2983342A CA2983342A1 CA 2983342 A1 CA2983342 A1 CA 2983342A1 CA 2983342 A CA2983342 A CA 2983342A CA 2983342 A CA2983342 A CA 2983342A CA 2983342 A1 CA2983342 A1 CA 2983342A1
Authority
CA
Canada
Prior art keywords
compound
independently selected
quinolizin
dihydrobenzo
int
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2983342A
Other languages
English (en)
French (fr)
Inventor
Christel Jeanne Marie Menet
Julien Georges Pierre-Olivier Doyon
Pieter Isabelle Roger CLAES
Brigitte Allart
Maxim Maria Paul De Wachter
Giovanni Alessandro Tricarico
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galapagos NV
Original Assignee
Galapagos NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos NV filed Critical Galapagos NV
Publication of CA2983342A1 publication Critical patent/CA2983342A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2983342A 2015-04-23 2016-04-19 Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders Abandoned CA2983342A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1506894.3A GB201506894D0 (en) 2015-04-23 2015-04-23 Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB1506894.3 2015-04-23
PCT/EP2016/058607 WO2016169911A1 (en) 2015-04-23 2016-04-19 Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Publications (1)

Publication Number Publication Date
CA2983342A1 true CA2983342A1 (en) 2016-10-27

Family

ID=53488521

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2983342A Abandoned CA2983342A1 (en) 2015-04-23 2016-04-19 Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Country Status (19)

Country Link
US (1) US10568879B2 (cg-RX-API-DMAC7.html)
EP (1) EP3286191B1 (cg-RX-API-DMAC7.html)
JP (1) JP6777652B2 (cg-RX-API-DMAC7.html)
KR (1) KR20170139142A (cg-RX-API-DMAC7.html)
CN (1) CN107531703B (cg-RX-API-DMAC7.html)
AR (1) AR104362A1 (cg-RX-API-DMAC7.html)
AU (1) AU2016251517A1 (cg-RX-API-DMAC7.html)
BR (1) BR112017022008A2 (cg-RX-API-DMAC7.html)
CA (1) CA2983342A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017011093A2 (cg-RX-API-DMAC7.html)
GB (1) GB201506894D0 (cg-RX-API-DMAC7.html)
IL (1) IL255109A0 (cg-RX-API-DMAC7.html)
MX (1) MX2017013382A (cg-RX-API-DMAC7.html)
PH (1) PH12017501911A1 (cg-RX-API-DMAC7.html)
RU (1) RU2017134551A (cg-RX-API-DMAC7.html)
SG (1) SG11201708671RA (cg-RX-API-DMAC7.html)
TW (1) TW201702243A (cg-RX-API-DMAC7.html)
WO (1) WO2016169911A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201706674B (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USD1117011S1 (en) * 2024-07-10 2026-03-10 Delta Electronics, Inc. Charging connector
USD1119767S1 (en) * 2024-07-10 2026-03-24 Delta Electronics, Inc. Charging connector

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3403649A1 (en) * 2017-05-16 2018-11-21 Bayer Pharma Aktiengesellschaft Inhibitors and antagonists of gpr84 for the treatment of endometriosis
CN106977483A (zh) * 2017-06-02 2017-07-25 遵义医学院 一种二氟烷基取代的黄酮醇、异黄酮醇和香豆素类化合物的合成方法
IL301709B2 (en) 2017-08-09 2025-07-01 Denali Therapeutics Inc Compounds, compositions and methods
TW201920129A (zh) 2017-09-01 2019-06-01 美商戴納立製藥公司 化合物、組合物及方法
US20210106582A1 (en) 2017-11-15 2021-04-15 Galapagos Nv Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases
WO2020007342A1 (zh) * 2018-07-06 2020-01-09 中国科学院上海药物研究所 联苯磷酸酯类化合物作为gpr84拮抗剂的应用
EP3924341A4 (en) 2019-02-13 2022-11-02 Denali Therapeutics Inc. Compounds, compositions and methods
CR20210426A (es) * 2019-02-13 2021-09-30 Denali Therapeutics Inc Compuestos, composiciones y métodos
PH12022551509A1 (en) * 2019-12-19 2023-04-24 Bayer Ag Furoindazole derivatives
WO2021123394A1 (en) 2019-12-20 2021-06-24 University Of Copenhagen G protein-coupled receptor modulators and a pharmaceutical composition
TW202241857A (zh) 2020-12-18 2022-11-01 美商戴納立製藥公司 化合物之固體形式
KR20230153387A (ko) 2021-02-02 2023-11-06 리미널 바이오사이언시스 리미티드 Gpr84 길항제 및 이의 용도
JP2024506858A (ja) 2021-02-02 2024-02-15 リミナル・バイオサイエンシーズ・リミテッド Gpr84アンタゴニストおよびその使用
WO2022179940A1 (en) 2021-02-23 2022-09-01 Bayer Aktiengesellschaft Furoindazole derivatives as gpr84 antagonists
WO2022218372A1 (zh) * 2021-04-14 2022-10-20 武汉人福创新药物研发中心有限公司 一种二氢嘧啶并异喹啉酮类衍生物及用途
WO2022229061A1 (en) 2021-04-29 2022-11-03 Bayer Aktiengesellschaft Furoindazole derivatives as antagonists or inhibitors of gpr84
WO2022263676A1 (en) 2021-06-18 2022-12-22 University Of Copenhagen Polysubstituted 4-hydroxypyridine and 4-hydroxyquinoline derivatives as gpr84 antagonists
CN115611944A (zh) 2021-07-15 2023-01-17 中国科学院上海药物研究所 不对称gpr84拮抗剂及其用途
WO2024083705A1 (en) 2022-10-18 2024-04-25 Bayer Aktiengesellschaft Furoindazole derivatives for the treatment of pain

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0926148A1 (en) * 1997-12-23 1999-06-30 Applied Research Systems Ars Holding N.V. Benzo (C)quinolizine derivatives, their preparation and use as 5-alphareductases inhibitors
WO2005050225A2 (en) * 2003-10-31 2005-06-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 84 (gpr84)
CA2621144A1 (en) 2005-09-02 2007-03-08 Arena Pharmaceuticals, Inc. Human g protein-coupled receptor and modulators thereof for the treatment of atherosclerosis and atherosclerotic disease and for the treatment of conditions related to mcp-1 expression
EP2619203A4 (en) 2010-09-20 2014-04-16 Glaxo Group Ltd TRICYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND APPLICATIONS THEREOF
AR089284A1 (es) * 2011-12-22 2014-08-13 Galapagos Nv Dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios
JP6293784B2 (ja) 2012-12-20 2018-03-14 ガラパゴス・ナムローゼ・フェンノートシャップGalapagos N.V. 炎症性障害の治療のための新規ジヒドロピリミジノイソキノリノン及びその医薬組成物(gpr84アンタゴニスト)
GB201411241D0 (en) 2014-06-25 2014-08-06 Galapagos Nv Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USD1117011S1 (en) * 2024-07-10 2026-03-10 Delta Electronics, Inc. Charging connector
USD1119767S1 (en) * 2024-07-10 2026-03-24 Delta Electronics, Inc. Charging connector

Also Published As

Publication number Publication date
JP2018513180A (ja) 2018-05-24
AU2016251517A1 (en) 2017-10-26
RU2017134551A (ru) 2019-04-04
TW201702243A (zh) 2017-01-16
US20190062325A1 (en) 2019-02-28
US10568879B2 (en) 2020-02-25
EP3286191B1 (en) 2020-07-29
CN107531703A (zh) 2018-01-02
CN107531703B (zh) 2020-09-01
KR20170139142A (ko) 2017-12-18
CO2017011093A2 (es) 2018-01-31
WO2016169911A1 (en) 2016-10-27
IL255109A0 (en) 2017-12-31
MX2017013382A (es) 2017-12-07
PH12017501911A1 (en) 2018-03-05
GB201506894D0 (en) 2015-06-10
AR104362A1 (es) 2017-07-12
EP3286191A1 (en) 2018-02-28
BR112017022008A2 (pt) 2018-07-03
ZA201706674B (en) 2019-07-31
JP6777652B2 (ja) 2020-10-28
SG11201708671RA (en) 2017-11-29

Similar Documents

Publication Publication Date Title
EP3286191B1 (en) Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
US11220499B2 (en) Dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
US12264156B2 (en) Compounds and pharmaceutical compositions thereof for the treatment of diseases
KR101990755B1 (ko) Cgrp 수용체 길항제
US9708312B2 (en) Dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (GPR84 antagonists)
EP3423445B1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis
WO2015197550A1 (en) Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
AU2017289315B2 (en) Heteroaromatic derivatives as NIK inhibitors
RS55807B1 (sr) Amido spirociklični amidni i sulfonamidni derivati
AU2014259477A1 (en) 3-(2-aminopyrimidin-4-yl)-5-(3-hydroxypropynyl)-1H-pyrrolo[2,3-c]pyridine derivatives as NIK inhibitors for the treatment of cancer
WO2021032323A1 (en) Fused pyrimidine compounds and pharmaceutical compositions thereof for the treatment of fibrotic diseases
US12240862B2 (en) Inhibitors of peptidylarginine deiminases
NZ626473B2 (en) Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
HK1201528B (en) Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20200831